These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32779246)

  • 1. The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes.
    Hicks D; Rafiee G; Schwalbe EC; Howell CI; Lindsey JC; Hill RM; Smith AJ; Adidharma P; Steel C; Richardson S; Pease L; Danilenko M; Crosier S; Joshi A; Wharton SB; Jacques TS; Pizer B; Michalski A; Williamson D; Bailey S; Clifford SC
    Neuropathol Appl Neurobiol; 2021 Feb; 47(2):236-250. PubMed ID: 32779246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study.
    Hill RM; Richardson S; Schwalbe EC; Hicks D; Lindsey JC; Crosier S; Rafiee G; Grabovska Y; Wharton SB; Jacques TS; Michalski A; Joshi A; Pizer B; Williamson D; Bailey S; Clifford SC
    Lancet Child Adolesc Health; 2020 Dec; 4(12):865-874. PubMed ID: 33222802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
    Goddard J; Castle J; Southworth E; Fletcher A; Crosier S; Martin-Guerrero I; García-Ariza M; Navajas A; Masliah-Planchon J; Bourdeaut F; Dufour C; Ayrault O; Goschzik T; Pietsch T; Sill M; Pfister SM; Rutkowski S; Richardson S; Hill RM; Williamson D; Bailey S; Schwalbe EC; Clifford SC; Hicks D
    Acta Neuropathol; 2023 May; 145(5):651-666. PubMed ID: 37014508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.
    Mynarek M; von Hoff K; Pietsch T; Ottensmeier H; Warmuth-Metz M; Bison B; Pfister S; Korshunov A; Sharma T; Jaeger N; Ryzhova M; Zheludkova O; Golanov A; Rushing EJ; Hasselblatt M; Koch A; Schüller U; von Deimling A; Sahm F; Sill M; Riemenschneider MJ; Dohmen H; Monoranu CM; Sommer C; Staszewski O; Mawrin C; Schittenhelm J; Brück W; Filipski K; Hartmann C; Meinhardt M; Pietschmann K; Haberler C; Slavc I; Gerber NU; Grotzer M; Benesch M; Schlegel PG; Deinlein F; von Bueren AO; Friedrich C; Juhnke BO; Obrecht D; Fleischhack G; Kwiecien R; Faldum A; Kortmann RD; Kool M; Rutkowski S
    J Clin Oncol; 2020 Jun; 38(18):2028-2040. PubMed ID: 32330099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of medulloblastomas with extensive nodularity (MBEN).
    Korshunov A; Sahm F; Stichel D; Schrimpf D; Ryzhova M; Zheludkova O; Golanov A; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2018 Aug; 136(2):303-313. PubMed ID: 29569031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
    von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
    Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
    Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
    Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker.
    Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Schrimpf D; Ghasemi DR; Pajtler KW; Antonelli M; Donofrio V; Mastronuzzi A; Rossi S; Camassei FD; Buccoliero AM; Haberler C; Slavc I; Dahiya S; Casalini B; Sievers P; Meyer J; Kumirova E; Zheludkova O; Golanov A; Jones DTW; Pfister SM; Kool M; von Deimling A
    Acta Neuropathol; 2020 Mar; 139(3):583-596. PubMed ID: 31781912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
    Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia.
    Alassiri AH; Alsufiani FM; Almutairi AA; Almohini IA; Aldosari MA; Essa MF
    Neurosciences (Riyadh); 2020 Jul; 25(3):218-221. PubMed ID: 32683405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
    Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
    Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study.
    Fukuoka K; Kurihara J; Shofuda T; Kagawa N; Yamasaki K; Ando R; Ishida J; Kanamori M; Kawamura A; Park YS; Kiyotani C; Akai T; Keino D; Miyairi Y; Sasaki A; Hirato J; Inoue T; Nakazawa A; Koh K; Nishikawa R; Date I; Nagane M; Ichimura K; Kanemura Y
    Acta Neuropathol Commun; 2023 Sep; 11(1):153. PubMed ID: 37749662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.